Article Dans Une Revue Cell Metabolism Année : 2014

NAD(+)-dependent activation of Sirt1 corrects the phenotype in a mouse model of mitochondrial disease

Raffaele Cerutti
  • Fonction : Auteur
Eija Pirinen
  • Fonction : Auteur
Costanza Lamperti
  • Fonction : Auteur
Silvia Marchet
  • Fonction : Auteur
Anthony A Sauve
  • Fonction : Auteur
Wei Li
  • Fonction : Auteur
Valerio Leoni
  • Fonction : Auteur
Eric A Schon
  • Fonction : Auteur
Johan Auwerx
  • Fonction : Auteur
Carlo Viscomi
  • Fonction : Auteur
Massimo Zeviani
  • Fonction : Auteur

Résumé

Mitochondrial disorders are highly heterogeneous conditions characterized by defects of the mitochondrial respiratory chain. Pharmacological activation of mitochondrial biogenesis has been proposed as an effective means to correct the biochemical defects and ameliorate the clinical phenotype in these severely disabling, often fatal, disorders. Pathways related to mitochondrial biogenesis are targets of Sirtuin1, a NAD(+)-dependent protein deacetylase. As NAD(+) boosts the activity of Sirtuin1 and other sirtuins, intracellular levels of NAD(+) play a key role in the homeostatic control of mitochondrial function by the metabolic status of the cell. We show here that supplementation with nicotinamide riboside, a natural NAD(+) precursor, or reduction of NAD(+) consumption by inhibiting the poly(ADP-ribose) polymerases, leads to marked improvement of the respiratory chain defect and exercise intolerance of the Sco2 knockout/knockin mouse, a mitochondrial disease model characterized by impaired cytochrome c oxidase biogenesis. This strategy is potentially translatable into therapy of mitochondrial disorders in humans.
Fichier principal
Vignette du fichier
2014_CellMetab_Cerutti.R.pdf (2) Télécharger le fichier
Origine Publication financée par une institution
licence

Dates et versions

hal-02369963 , version 1 (21-02-2025)

Licence

Identifiants

Citer

Raffaele Cerutti, Eija Pirinen, Costanza Lamperti, Silvia Marchet, Anthony A Sauve, et al.. NAD(+)-dependent activation of Sirt1 corrects the phenotype in a mouse model of mitochondrial disease. Cell Metabolism, 2014, 19 (6), pp.1042-9. ⟨10.1016/j.cmet.2014.04.001⟩. ⟨hal-02369963⟩

Collections

CNRS SITE-ALSACE
30 Consultations
0 Téléchargements

Altmetric

Partager

More